Research graph
References from Integrated structural approaches in immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
LAG-3 as the third checkpoint inhibitor
10.1038/s41590-023-01569-z · 2023 · External reference
Preclinical development in radiopharmaceutical therapy for prostate cancer
10.1053/j.semnuclmed.2023.06.007 · 2023 · External reference
CAR-T cell combination therapy: the next revolution in cancer treatment
10.1186/s12935-022-02778-6 · 2022 · External reference
Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions
10.3389/fimmu.2025.1647066 · 2025 · External reference
Unresolved reference
External reference
Recent advances in non-small cell lung cancer targeted therapy; an update review
10.1186/s12935-023-02990-y · 2023 · External reference
Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies
10.3390/cancers17020282 · 2025 · External reference
Recent advances and remaining challenges in lung cancer therapy
10.1097/cm9.0000000000002991 · 2024 · External reference
Coinhibitory pathways in immunotherapy for cancer
10.1146/annurev-immunol-032414-112049 · 2016 · External reference
Monoclonal antibodies in breast cancer: a critical appraisal
10.1016/j.critrevonc.2023.103915 · 2023 · External reference
PD-L1 Glycosylation and its impact on binding to clinical antibodies
10.1021/acs.jproteome.0c00521 · 2021 · External reference
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
10.1073/pnas.1811067116 · 2019 · External reference
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
10.1136/jitc-2023-007336 · 2023 · External reference
Surface glycan targeting for cancer nano-immunotherapy
10.1016/j.jconrel.2022.01.004 · 2022 · External reference
Cytokines in the treatment of cancer
10.1089/jir.2018.0019 · 2019 · External reference
Advanced glycation end products in diabetes, cancer and phytochemical therapy
10.1016/j.drudis.2020.07.003 · 2020 · External reference
Determinants of the efficacy of viro-immunotherapy: a review
10.1016/j.cytogfr.2020.07.001 · 2020 · External reference
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
10.4161/mabs.28965 · 2014 · External reference
10.1016/j.semcancer.2017.10.003
10.1016/j.semcancer.2017.10.003 · 2018 · External reference
Mechanism of action of immunotherapy
10.1053/j.seminoncol.2014.09.004 · 2014 · External reference
The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group
10.1038/s41523-021-00346-1 · 2021 · External reference
Progress in research on cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and bladder cancer
10.32948/auo.2019.01.22 · 2019 · External reference
Immunotherapy for head and neck cancer: present and future
10.1016/j.critrevonc.2022.103679 · 2022 · External reference
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer
10.1097/ppo.0b013e3181eacbc4 · 2010 · External reference
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
10.1038/s41591-018-0010-1 · 2018 · External reference
Immunotherapy in melanoma: recent advances and future directions
10.1016/j.ejso.2016.07.145 · 2017 · External reference
HMGB1 expression levels correlate with response to immunotherapy in non-small cell lung cancer
2024 · External reference
RAGE-mediated inflammation in patients with septic shock
10.1016/j.jss.2016.01.019 · 2016 · External reference
CTLA-4: From mechanism to autoimmune therapy
10.1016/j.intimp.2020.106221 · 2020 · External reference
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
10.3389/fimmu.2022.956090 · 2022 · External reference
VIRO-immune therapy: a new strategy for treatment of pancreatic cancer
10.3748/wjg.v22.i2.748 · 2016 · External reference
Emerging new therapeutic antibody derivatives for cancer treatment
10.1038/s41392-021-00868-x · 2022 · External reference
Immunomodulatory effects of carbohydrates and advanced glycation end products
10.5897/bmbr2014-0237 · 2015 · External reference
Cell therapy with TILs: training and taming T cells to fight cancer
10.3389/fimmu.2021.690499 · 2021 · External reference
Regulation of PD-L1 glycosylation and advances in cancer immunotherapy
10.1016/j.canlet.2025.217498 · 2025 · External reference
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
2016 · External reference
Regulatory mechanisms of PD-1/PD-L1 in cancers
10.1186/s12943-024-02023-w · 2024 · External reference
Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody
10.1016/j.ijpharm.2022.121969 · 2022 · External reference
Role of receptor for advanced glycation end products in the complication and progression of various types of cancers
10.1016/j.bbagen.2015.05.020 · 2015 · External reference
Recent clinical researches and technological development in TIL therapy
10.1007/s00262-024-03793-4 · 2024 · External reference
Engineering-enhanced CAR T cells for improved cancer therapy
10.1038/s43018-021-00241-5 · 2021 · External reference
CAR T cell therapy: a new era for cancer treatment
2019 · External reference
CAR T-cells for cancer therapy
10.1080/02648725.2018.1430465 · 2017 · External reference
Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?
10.1038/ncponc0666 · 2006 · External reference
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
10.1016/j.molmed.2014.10.009 · 2015 · External reference
Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy
10.3389/fimmu.2022.1038226 · 2023 · External reference
Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations
10.1053/j.seminoncol.2016.06.008 · 2016 · External reference
Cytokines in cancer therapy
10.1016/s0165-2478(00)00247-9 · 2000 · External reference
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
2009 · External reference
Monoclonal antibodies for the treatment of cancer
2017 · External reference
Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer
10.1080/2162402x.2021.1874159 · 2021 · External reference
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
10.1136/jitc-2025-012391 · 2025 · External reference
Harnessing cytokines and chemokines for cancer therapy
10.1038/s41571-021-00588-9 · 2022 · External reference
Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer
10.1038/s41598-023-44211-6 · 2023 · External reference
Role of advanced glycation end products in carcinogenesis and their therapeutic implications
10.2174/1381612825666190130145549 · 2018 · External reference
Immunotherapy and targeted therapy—the new roadmap in cancer treatment
10.21037/atm.2019.05.58 · 2019 · External reference
Advanced glycation end-products acting as immunomodulators for chronic inflammation, inflammaging and carcinogenesis in patients with diabetes and immune-related diseases
10.3390/biomedicines12081699 · 2024 · External reference
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
10.1136/jitc-2020-002086 · 2021 · External reference
Immune checkpoint inhibitors in cancer therapy
10.3390/curroncol29050247 · 2022 · External reference
PD-L1 and PD-1 in immune regulation and their implications in blood cancers
10.1016/j.adcanc.2024.100125 · 2024 · External reference
Targeted cancer therapies: clinical pearls for primary care
10.46747/cfp.6807515 · 2022 · External reference
Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications
10.3389/fimmu.2022.947648 · 2022 · External reference
Bispecific antibodies in cancer therapy: target selection and regulatory requirements
10.1016/j.apsb.2023.05.023 · 2023 · External reference
CTLA-4 blockade: therapeutic potential in cancer treatments
10.2147/ott.s4833 · 2010 · External reference
Immunomodulation by processed animal feed: the role of maillard reaction products and advanced glycation end-products (AGEs)
10.3389/fimmu.2018.02088 · 2018 · External reference
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
10.1007/s12032-018-1080-0 · 2018 · External reference
Unresolved reference
External reference
The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer
10.1016/j.ctrv.2022.102500 · 2023 · External reference
Immunogenicity of CAR T cells in cancer therapy
10.1038/s41571-021-00476-2 · 2021 · External reference
Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer
10.1002/ctm2.901 · 2022 · External reference
Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future
10.1158/1078-0432.ccr-22-1922 · 2023 · External reference
Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer
10.1080/10717544.2022.2120566 · 2022 · External reference
Exosome-based immunotherapy: a promising approach for cancer treatment
10.1186/s12943-020-01278-3 · 2020 · External reference
Altered glycosylation in cancer: molecular functions and therapeutic potential
10.1002/cac2.12610 · 2024 · External reference
Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines
2015 · External reference
Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges
10.1016/j.ctrv.2023.102520 · 2023 · External reference
Monoclonal antibodies in cancer therapy
10.3390/antib9030034 · 2020 · External reference
Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas
10.3389/fimmu.2021.721830 · 2021 · External reference
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
10.1186/s12943-025-02305-x · 2025 · External reference
Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer
2024 · External reference
Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry
10.4161/mabs.36313 · 2014 · External reference
Altered glycosylation in cancer: molecular functions and therapeutic potential
10.1002/cac2.12610 · ExternalCitation · doi-reference
Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer
10.1002/ctm2.901 · ExternalCitation · doi-reference
Recent clinical researches and technological development in TIL therapy
10.1007/s00262-024-03793-4 · ExternalCitation · doi-reference
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
10.1007/s12032-018-1080-0 · ExternalCitation · doi-reference
PD-L1 and PD-1 in immune regulation and their implications in blood cancers
10.1016/j.adcanc.2024.100125 · ExternalCitation · doi-reference
Bispecific antibodies in cancer therapy: target selection and regulatory requirements
10.1016/j.apsb.2023.05.023 · ExternalCitation · doi-reference
Role of receptor for advanced glycation end products in the complication and progression of various types of cancers
10.1016/j.bbagen.2015.05.020 · ExternalCitation · doi-reference
Regulation of PD-L1 glycosylation and advances in cancer immunotherapy
10.1016/j.canlet.2025.217498 · ExternalCitation · doi-reference
Immunotherapy for head and neck cancer: present and future
10.1016/j.critrevonc.2022.103679 · ExternalCitation · doi-reference
Monoclonal antibodies in breast cancer: a critical appraisal
10.1016/j.critrevonc.2023.103915 · ExternalCitation · doi-reference
The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer
10.1016/j.ctrv.2022.102500 · ExternalCitation · doi-reference
Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges
10.1016/j.ctrv.2023.102520 · ExternalCitation · doi-reference
Determinants of the efficacy of viro-immunotherapy: a review
10.1016/j.cytogfr.2020.07.001 · ExternalCitation · doi-reference
Advanced glycation end products in diabetes, cancer and phytochemical therapy
10.1016/j.drudis.2020.07.003 · ExternalCitation · doi-reference
Immunotherapy in melanoma: recent advances and future directions
10.1016/j.ejso.2016.07.145 · ExternalCitation · doi-reference
Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody
10.1016/j.ijpharm.2022.121969 · ExternalCitation · doi-reference
CTLA-4: From mechanism to autoimmune therapy
10.1016/j.intimp.2020.106221 · ExternalCitation · doi-reference
Surface glycan targeting for cancer nano-immunotherapy
10.1016/j.jconrel.2022.01.004 · ExternalCitation · doi-reference
RAGE-mediated inflammation in patients with septic shock
10.1016/j.jss.2016.01.019 · ExternalCitation · doi-reference
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
10.1016/j.molmed.2014.10.009 · ExternalCitation · doi-reference
10.1016/j.semcancer.2017.10.003
10.1016/j.semcancer.2017.10.003 · ExternalCitation · doi-reference
Cytokines in cancer therapy
10.1016/s0165-2478(00)00247-9 · ExternalCitation · doi-reference
PD-L1 Glycosylation and its impact on binding to clinical antibodies
10.1021/acs.jproteome.0c00521 · ExternalCitation · doi-reference
Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?
10.1038/ncponc0666 · ExternalCitation · doi-reference
Emerging new therapeutic antibody derivatives for cancer treatment
10.1038/s41392-021-00868-x · ExternalCitation · doi-reference
The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group
10.1038/s41523-021-00346-1 · ExternalCitation · doi-reference
Immunogenicity of CAR T cells in cancer therapy
10.1038/s41571-021-00476-2 · ExternalCitation · doi-reference
Harnessing cytokines and chemokines for cancer therapy
10.1038/s41571-021-00588-9 · ExternalCitation · doi-reference
LAG-3 as the third checkpoint inhibitor
10.1038/s41590-023-01569-z · ExternalCitation · doi-reference
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
10.1038/s41591-018-0010-1 · ExternalCitation · doi-reference
Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer
10.1038/s41598-023-44211-6 · ExternalCitation · doi-reference
Engineering-enhanced CAR T cells for improved cancer therapy
10.1038/s43018-021-00241-5 · ExternalCitation · doi-reference
Mechanism of action of immunotherapy
10.1053/j.seminoncol.2014.09.004 · ExternalCitation · doi-reference
Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations
10.1053/j.seminoncol.2016.06.008 · ExternalCitation · doi-reference
Preclinical development in radiopharmaceutical therapy for prostate cancer
10.1053/j.semnuclmed.2023.06.007 · ExternalCitation · doi-reference
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
10.1073/pnas.1811067116 · ExternalCitation · doi-reference
CAR T-cells for cancer therapy
10.1080/02648725.2018.1430465 · ExternalCitation · doi-reference
Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer
10.1080/10717544.2022.2120566 · ExternalCitation · doi-reference
Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer
10.1080/2162402x.2021.1874159 · ExternalCitation · doi-reference
Cytokines in the treatment of cancer
10.1089/jir.2018.0019 · ExternalCitation · doi-reference
Recent advances and remaining challenges in lung cancer therapy
10.1097/cm9.0000000000002991 · ExternalCitation · doi-reference
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer
10.1097/ppo.0b013e3181eacbc4 · ExternalCitation · doi-reference
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
10.1136/jitc-2020-002086 · ExternalCitation · doi-reference
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
10.1136/jitc-2023-007336 · ExternalCitation · doi-reference
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
10.1136/jitc-2025-012391 · ExternalCitation · doi-reference
Coinhibitory pathways in immunotherapy for cancer
10.1146/annurev-immunol-032414-112049 · ExternalCitation · doi-reference
Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future
10.1158/1078-0432.ccr-22-1922 · ExternalCitation · doi-reference
CAR-T cell combination therapy: the next revolution in cancer treatment
10.1186/s12935-022-02778-6 · ExternalCitation · doi-reference
Recent advances in non-small cell lung cancer targeted therapy; an update review
10.1186/s12935-023-02990-y · ExternalCitation · doi-reference
Exosome-based immunotherapy: a promising approach for cancer treatment
10.1186/s12943-020-01278-3 · ExternalCitation · doi-reference
Regulatory mechanisms of PD-1/PD-L1 in cancers
10.1186/s12943-024-02023-w · ExternalCitation · doi-reference
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
10.1186/s12943-025-02305-x · ExternalCitation · doi-reference
Immunotherapy and targeted therapy—the new roadmap in cancer treatment
10.21037/atm.2019.05.58 · ExternalCitation · doi-reference
CTLA-4 blockade: therapeutic potential in cancer treatments
10.2147/ott.s4833 · ExternalCitation · doi-reference
Role of advanced glycation end products in carcinogenesis and their therapeutic implications
10.2174/1381612825666190130145549 · ExternalCitation · doi-reference
Progress in research on cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and bladder cancer
10.32948/auo.2019.01.22 · ExternalCitation · doi-reference
Immunomodulation by processed animal feed: the role of maillard reaction products and advanced glycation end-products (AGEs)
10.3389/fimmu.2018.02088 · ExternalCitation · doi-reference
Cell therapy with TILs: training and taming T cells to fight cancer
10.3389/fimmu.2021.690499 · ExternalCitation · doi-reference
Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas
10.3389/fimmu.2021.721830 · ExternalCitation · doi-reference
Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy
10.3389/fimmu.2022.1038226 · ExternalCitation · doi-reference
Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications
10.3389/fimmu.2022.947648 · ExternalCitation · doi-reference
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
10.3389/fimmu.2022.956090 · ExternalCitation · doi-reference
Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions
10.3389/fimmu.2025.1647066 · ExternalCitation · doi-reference
Monoclonal antibodies in cancer therapy
10.3390/antib9030034 · ExternalCitation · doi-reference
Advanced glycation end-products acting as immunomodulators for chronic inflammation, inflammaging and carcinogenesis in patients with diabetes and immune-related diseases
10.3390/biomedicines12081699 · ExternalCitation · doi-reference
Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies
10.3390/cancers17020282 · ExternalCitation · doi-reference
Immune checkpoint inhibitors in cancer therapy
10.3390/curroncol29050247 · ExternalCitation · doi-reference
VIRO-immune therapy: a new strategy for treatment of pancreatic cancer
10.3748/wjg.v22.i2.748 · ExternalCitation · doi-reference
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
10.4161/mabs.28965 · ExternalCitation · doi-reference
Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry
10.4161/mabs.36313 · ExternalCitation · doi-reference
Targeted cancer therapies: clinical pearls for primary care
10.46747/cfp.6807515 · ExternalCitation · doi-reference
Immunomodulatory effects of carbohydrates and advanced glycation end products
10.5897/bmbr2014-0237 · ExternalCitation · doi-reference
